A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects

Clinical Trial Summary

A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to <18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase) or PB-06-005 (naïve treatment with taliglucerase alfa).

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04189601` - Complement Activation in the Lysosomal Storage Disorders
Completed	`NCT02536937` - A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	Phase 1
Completed	`NCT02536911` - A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	Phase 1
Completed	`NCT04430881` - A National Study in Patients With Unexplained Splenomegaly
Terminated	`NCT04094181` - A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
Completed	`NCT00391625` - Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)	Phase 1/Phase 2
Completed	`NCT03625882` - Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Active, not recruiting	`NCT05526664` - Omics Gaucher Study: Multiomic Approach
Completed	`NCT02536755` - Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies	Phase 3
Recruiting	`NCT01344096` - Thrombocytopathy in Gaucher Disease Patients	N/A
Completed	`NCT01881633` - A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers	Phase 1
Recruiting	`NCT06116071` - Biomarkers Related to Bone in Pediatric Gaucher Disease
Recruiting	`NCT01951989` - Intra-monocyte Imiglucerase Kinetics in Gaucher Disease	Phase 2
Completed	`NCT00258778` - Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)	Phase 1
Recruiting	`NCT04388969` - World Data on Ambroxol for Patients With GD and GBA Related PD
Recruiting	`NCT05992532` - GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Terminated	`NCT04145037` - Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease	Phase 1/Phase 2
Completed	`NCT00302146` - Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
Active, not recruiting	`NCT02605603` - SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
Completed	`NCT02053896` - A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease	Phase 2

NCT number	NCT01411228
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	September 2011
Completion date	August 2014

A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms